{
  "eccn": "1C991.c.3",
  "normalized": "1C991.C.3",
  "history": [
    {
      "version": "2017-01-15",
      "fetchedAt": "2025-10-02T20:33:28.357Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2017-01-15/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2017-07-07",
      "fetchedAt": "2025-10-02T20:33:28.904Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2017-07-07/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2017-08-15",
      "fetchedAt": "2025-10-02T20:33:29.324Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2017-08-15/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2017-12-27",
      "fetchedAt": "2025-10-02T20:33:29.759Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2017-12-27/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-01-08",
      "fetchedAt": "2025-10-02T20:33:30.194Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-01-08/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-04-02",
      "fetchedAt": "2025-10-02T20:33:30.716Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-04-02/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-04-05",
      "fetchedAt": "2025-10-02T20:33:31.145Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-04-05/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-08-30",
      "fetchedAt": "2025-10-02T20:33:31.567Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-08-30/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-10-24",
      "fetchedAt": "2025-10-02T20:33:31.990Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-10-24/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-11-02",
      "fetchedAt": "2025-10-02T20:33:32.381Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-11-02/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "License Requirements",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2018-12-20",
      "fetchedAt": "2025-10-02T20:33:32.762Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2018-12-20/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2019-05-23",
      "fetchedAt": "2025-10-02T20:33:33.148Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2019-05-23/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-01-06",
      "fetchedAt": "2025-10-02T20:33:33.561Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-01-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-03-09",
      "fetchedAt": "2025-10-02T20:33:33.960Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-03-09/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-06-17",
      "fetchedAt": "2025-10-02T20:33:34.354Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-06-17/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-06-29",
      "fetchedAt": "2025-10-02T20:33:34.750Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-06-29/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-09-11",
      "fetchedAt": "2025-10-02T20:33:35.161Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-09-11/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-10-05",
      "fetchedAt": "2025-10-02T20:33:35.641Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-10-05/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-10-06",
      "fetchedAt": "2025-10-02T20:33:36.026Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-10-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2020-12-04",
      "fetchedAt": "2025-10-02T20:33:36.431Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2020-12-04/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-01-06",
      "fetchedAt": "2025-10-02T20:33:36.829Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-01-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items controlled).",
        "Medical products containing botulinum toxins controlled by ECCN 1C351.d.3 or conotoxins controlled by ECCN 1C351.d.6;"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\na. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, “immunotoxin” is defined as an antibody-toxin conjugate intended to destroy specific target cells (e.g., tumor cells) that bear antigens homologous to the antibody. For the purpose of this entry, “medical products” are: (1) Pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, “diagnostic and food testing kits” are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, “vaccine” is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "text",
            "text": "a. Vaccines against items controlled by ECCN 1C351, 1C353 or 1C354."
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-01-07",
      "fetchedAt": "2025-10-02T20:33:37.217Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-01-07/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-01-14",
      "fetchedAt": "2025-10-02T20:33:37.609Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-01-14/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-03-29",
      "fetchedAt": "2025-10-02T20:33:37.994Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-03-29/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-09-20",
      "fetchedAt": "2025-10-02T20:33:38.383Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-09-20/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-10-05",
      "fetchedAt": "2025-10-02T20:33:38.778Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-10-05/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2021-12-06",
      "fetchedAt": "2025-10-02T20:33:39.172Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2021-12-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-01-06",
      "fetchedAt": "2025-10-02T20:33:39.613Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-01-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-01-19",
      "fetchedAt": "2025-10-02T20:33:40.017Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-01-19/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-02-03",
      "fetchedAt": "2025-10-02T20:33:40.404Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-02-03/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-05-26",
      "fetchedAt": "2025-10-02T20:33:40.828Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-05-26/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-08-15",
      "fetchedAt": "2025-10-02T20:33:41.210Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-08-15/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2022-10-07",
      "fetchedAt": "2025-10-02T20:33:41.595Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2022-10-07/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions, (2) prepackaged for distribution as clinical or medical products, and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE>\n<HED><I>Technical Note:</I></HED>\n<P><I>For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></P></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-01-17",
      "fetchedAt": "2025-10-02T20:33:41.990Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-01-17/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-02-24",
      "fetchedAt": "2025-10-02T20:33:42.390Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-02-24/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774 - The Commerce Control List"
      },
      "breadcrumbs": [
        "List of Items Controlled",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-08-18",
      "fetchedAt": "2025-10-02T20:33:42.783Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-08-18/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "List Based License Exceptions (See Part 740 for a Description of All License Exceptions)",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-10-18",
      "fetchedAt": "2025-10-02T20:33:43.173Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-10-18/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "List Based License Exceptions (See Part 740 for a Description of All License Exceptions)",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-11-17",
      "fetchedAt": "2025-10-02T20:33:43.584Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-11-17/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "List Based License Exceptions (See Part 740 for a Description of All License Exceptions)",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2023-12-08",
      "fetchedAt": "2025-10-02T20:33:43.980Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2023-12-08/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-03-08",
      "fetchedAt": "2025-10-02T20:33:44.401Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-03-08/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-03-13",
      "fetchedAt": "2025-10-02T20:33:44.826Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-03-13/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-04-04",
      "fetchedAt": "2025-10-02T20:33:45.229Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-04-04/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-04-19",
      "fetchedAt": "2025-10-02T20:33:45.630Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-04-19/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-05-30",
      "fetchedAt": "2025-10-02T20:33:46.051Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-05-30/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-06-12",
      "fetchedAt": "2025-10-02T20:33:46.460Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-06-12/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-09-06",
      "fetchedAt": "2025-10-02T20:33:46.879Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-09-06/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-10-23",
      "fetchedAt": "2025-10-02T20:33:47.324Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-10-23/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    },
    {
      "version": "2024-12-02",
      "fetchedAt": "2025-10-02T20:33:47.757Z",
      "sourceUrl": "https://www.ecfr.gov/api/versioner/v1/full/2024-12-02/title-15?format=xml",
      "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "title": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
      "category": "1",
      "group": "1C",
      "supplement": {
        "number": "1",
        "heading": "Supplement No. 1 to Part 774—The Commerce Control List"
      },
      "breadcrumbs": [
        "C. “Materials”",
        "1C991 Vaccines, immunotoxins, medical products, diagnostic and food testing kits, as follows (see List of Items Controlled).",
        "Medical products that contain any of the following:"
      ],
      "ancestors": [
        "1C991",
        "1C991.c"
      ],
      "text": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.\nRelated Definitions:\nFor the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered.\nItems:\nTechnical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
      "structure": {
        "identifier": "1C991.c.3",
        "heading": "Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "label": "1C991.c.3 – Also see 21 CFR 314.410 for FDA requirements concerning exports of new drugs and new drug substances.",
        "content": [
          {
            "type": "text",
            "text": "Related Definitions:"
          },
          {
            "type": "text",
            "text": "For the purpose of this entry, 'immunotoxins' are monoclonal antibodies linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact. For the purpose of this entry, 'medical products' are: (1) Pharmaceutical formulations designed for testing and human (or veterinary) administration in the treatment of medical conditions; (2) prepackaged for distribution as clinical or medical products; and (3) approved by the U.S. Food and Drug Administration either to be marketed as clinical or medical products or for use as an “Investigational New Drug” (IND) (see 21 CFR part 312). For the purpose of this entry, 'diagnostic and food testing kits' are specifically developed, packaged and marketed for diagnostic or public health purposes. Biological toxins in any other configuration, including bulk shipments, or for any other end-uses are controlled by ECCN 1C351. For the purpose of this entry, 'vaccine' is defined as a medicinal (or veterinary) product in a pharmaceutical formulation, approved by the U.S. Food and Drug Administration or the U.S. Department of Agriculture to be marketed as a medical (or veterinary) product or for use in clinical trials, that is intended to stimulate a protective immunological response in humans or animals in order to prevent disease in those to whom or to which it is administered."
          },
          {
            "type": "text",
            "text": "Items:"
          },
          {
            "type": "html",
            "tag": "NOTE",
            "html": "<NOTE><HED><I>Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.</I></HED></NOTE>",
            "text": "Technical Note: For purposes of the controls described in this ECCN, 'toxins' refers to those toxins, or their subunits, controlled under ECCN 1C351.d.",
            "id": null
          }
        ],
        "isEccn": true,
        "boundToParent": false,
        "requireAllChildren": false
      }
    }
  ]
}